CMPS250117C2500
- 1.46
- 0.000.00%
COMPASS Pathways Newsroom
Compass Pathways Common Stock To Be Added To The Nasdaq Biotechnology Index
Earnings Week Ahead: FDX, NKE, CCL, BB, ACN, MU, and More
Compass Pathways to Participate in December Investor Conferences
COMPASS Pathways: Institutional Pressure Amid $43M Market Cap Decline, What's Next For This Psychedelics Co?
COMPASS Pathways Plc (NASDAQ:CMPS) Has Caught the Attention of Institutional Investors Who Hold a Sizeable 29% Stake
European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday
Despegar.com, Zai Lab, Bloom Energy And Other Big Stocks Moving Higher On Friday
Express News | U.S.-Listed Shares of ATAI Life Sciences up 9.1%
Express News | GH Research Shares up 4.1%
Express News | Compass Pathways Shares up 11.9%
Express News | Shares of Psychedelic Drug Developers Rise After Rfk Jr Picked for Top US Health Agency Role
RFK and the 'MAHA Trade': Vaccine Makers Down, Psychedelic Shares up
AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?
Strategic Opportunity in COMPASS Pathways Amid Extended Phase 3 Trials and Conservative Price Target
Massachusetts Psychedelics Legalization Initiative Poised to Fail
Top 3 Health Care Stocks You'll Regret Missing In November
BTIG Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $12
Morgan Stanley Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $17
Massachusetts may become the next stop for legalization, is it a good investment opportunity for psychedelic drug concept stocks?
On Tuesday, Massachusetts voters will decide whether the state will legalize psilocybin, a hallucinogenic compound found in "magic mushrooms," worth noting for related concept stocks.
Legalizing Psychedelics: Is Massachusetts Next?